Global Herceptin Biosimilars Market, By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Others), Dosage (150mg/single-dose vial, 420mg/multidose vial), End-Users (Specialty Clinics, Hospitals, Oncology Centers, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Herceptin biosimilars market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 6.60% in the above-mentioned research forecast period. Increasing incidence of cancers globally and rising focus on the development of Herceptin therapeutic biosimilars.
Moreover increasing research and development and increasing awareness regarding cancer treatment also boost up the market growth. Moreover, increasing healthcare expenditure and presence of novel pipeline products act as opportunity for the market growth. But, sometimes adverse effect related caused by Herceptin biosimilars, stringent regulations regarding the approval of Herceptin biosimilars and presence of alternative treatment options may hamper the global Herceptin biosimilars market.
Herceptin (Trastuzumab) is a monoclonal antibody which provides effective result by binding with the human epidermal growth factor receptor 2 (HER2). In several types of cancer HER2 gene is overexpressed which leads to cancer development due to uncontrollable growth of cells. Herceptin received first approval in 1998 indicated for the treatment of metastatic breast cancer. Now approximately five Herceptin biosimilar drugs have been approved in the U.S. market. Herceptin biosimilar drug is available at the cost of USD 70,000 for one year of treatment and has been proved as the standard treatment of breast cancer.
This herceptin biosimilars market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Herceptin Biosimilars Market Scope and Market Size
Herceptin biosimilars market is segmented on the basis of application, dosage, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of application, the herceptin biosimilars market is segmented into breast cancer, colorectal cancer, leukemia, lymphoma, others.
- On the basis of dosage, the herceptin biosimilars market is segmented into 150mg/single-dose vial, 420mg/multidose vial.
- On the basis of end- users, the herceptin biosimilars market has also been segmented into specialty clinics, hospitals, oncology centers, others.
- On the basis of distribution channel, the herceptin biosimilars market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Herceptin biosimilars Market Country Level Analysis
Herceptin biosimilars market is analysed and market size information is provided by country, application, dosage, end-users and distribution channel as referenced above.
The countries covered in the Herceptin biosimilars market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
North America accounts the largest market share due to the presence of high healthcare expenditure and favourable reimbursement policies for Herceptin biosimilars. Europe accounts the second largest market share due to increasing disposable income and introduction of new Herceptin biosimilars. Asia-Pacific is expected to account for the largest market share over coming years for the Herceptin biosimilars market due to rapid adoption of Herceptin biosimilars and increasing patient pool.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Herceptin biosimilars market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Herceptin Biosimilars Market Share Analysis
Herceptin biosimilars market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Herceptin biosimilars market.
The major players covered in the herceptin biosimilars market are Amgen Inc., AryoGen Pharmed, Biocon, Celltrion Healthcare Co.,Ltd., Pfizer Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Shanghai Henlius Biotech, Inc., Gedeon Richter Plc., Genor Biopharma Company Ltd, MABION S.A, Mylan N.V., F. Hoffmann-La Roche Ltd, Samsung Bioepis, ACROBiosystems, Genentech, USA Inc., AstraZeneca, Halozyme, Inc., Teva Pharmaceuticals USA, Inc., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available: Global Herceptin Biosimilars Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.